{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:05:47Z","timestamp":1784091947484,"version":"3.55.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82201853,82504941"],"award-info":[{"award-number":["82201853,82504941"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer, as a prevalent malignant tumor among women worldwide, has its malignant progression closely linked to angiogenesis mechanisms. Research indicates that combining anti-angiogenic drugs can promote tumor vascular normalization, thereby improving the delivery of chemotherapeutic agents and reversing the drug-resistant microenvironment. Some clinical studies have confirmed that such combination regimens can enhance pathological response rates (pCR). This paper aims to systematically evaluate the clinical value of angiogenesis inhibitors in neoadjuvant chemotherapy (NACT) for breast cancer and provide evidence-based guidance to optimize treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched the PubMed and Web of Science databases up to July 16, 2025, to identify randomized controlled trials (RCTs) comparing angiogenesis inhibitor-based NACT regimens with angiogenesis inhibitor-free regimens in breast cancer patients. Using random effects models, we calculated pooled odds ratios and hazard ratios with 95% confidence intervals for pCR, disease-free survival (DFS), overall survival (OS), objective response rate (ORR), and adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This analysis included 10 RCTs (8,069 patients). The results showed that NACT containing angiogenesis inhibitors significantly increased the pCR rate (22.59% vs. 29.88%). Subgroup analysis indicated no statistically significant improvement in pCR among hormone receptor-positive patients, whereas in triple-negative breast cancer (TNBC), the pCR rate was significantly elevated (32.42% vs. 42.46%). Regarding survival outcomes, no significant differences were observed in either DFS or OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combination of bevacizumab with NACT can improve the pCR rate, with this effect being particularly pronounced in TNBC. However, current research has not yet reached a consensus on whether it can improve OS, and there remains a lack of clear biomarkers for predicting treatment efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD420261411787.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1830676","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:22:05Z","timestamp":1784089325000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant chemotherapy with angiogenesis inhibitor in early-stage breast cancer: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiangzhuo","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"National Clinical Key Specialty (General Surgery)\/National Clinical Research Center for Digestive Diseases\/Sichuan Clinical Research Center for Digestive Diseases","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"National Clinical Key Specialty (General Surgery)\/National Clinical Research Center for Digestive Diseases\/Sichuan Clinical Research Center for Digestive Diseases","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"National Clinical Key Specialty (General Surgery)\/National Clinical Research Center for Digestive Diseases\/Sichuan Clinical Research Center for Digestive Diseases","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"National Clinical Key Specialty (General Surgery)\/National Clinical Research Center for Digestive Diseases\/Sichuan Clinical Research Center for Digestive Diseases","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"National Clinical Key Specialty (General Surgery)\/National Clinical Research Center for Digestive Diseases\/Sichuan Clinical Research Center for Digestive Diseases","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"National Clinical Key Specialty (General Surgery)\/National Clinical Research Center for Digestive Diseases\/Sichuan Clinical Research Center for Digestive Diseases","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"National Clinical Key Specialty (General Surgery)\/National Clinical Research Center for Digestive Diseases\/Sichuan Clinical Research Center for Digestive Diseases","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120645","article-title":"Management of tumor growth and angiogenesis in triple-negative breast cancer by using redox nanoparticles","volume":"269","author":"Shashni","year":"2021","journal-title":"Biomaterials"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2023.0515","article-title":"Research progress in tumor angiogenesis and drug resistance in breast cancer","volume":"21","author":"Mou","year":"2024","journal-title":"Cancer Biol Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-197203000-00014","article-title":"Anti-angiogenesis: new concept for therapy of solid tumors","volume":"175","author":"Folkman","year":"1972","journal-title":"Ann Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.103921","article-title":"The optimal timing between neoadjuvant therapy and surgery of breast cancer: A brief systematic review of the literature","volume":"183","author":"Lorenzo","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1226360","article-title":"Immunotherapies targeting tumor vasculature: challenges and opportunities","volume":"14","author":"Dianat-Moghadam","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2021.10.029","article-title":"CRISPR\/Cas9 in cancer therapy: A review with a special focus on tumor angiogenesis","volume":"192","author":"Hariprabu","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.07.024","article-title":"Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization","volume":"26","author":"Wang","year":"2021","journal-title":"Drug Discov Today"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.03.042","article-title":"Extracellular vesicles derived from dendritic cells loaded with VEGF-A siRNA and doxorubicin reduce glioma angiogenesis in vitro","volume":"369","author":"Shamshiripour","year":"2024","journal-title":"J Control Release"},{"key":"B10","doi-asserted-by":"publisher","first-page":"104669","DOI":"10.1016\/j.breast.2025.104669","article-title":"Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy","author":"Shai","year":"2025","journal-title":"Breast"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102585","article-title":"Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II\/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial","volume":"71","author":"Liang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-4313","article-title":"Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial","volume":"28","author":"Chen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.05.006","article-title":"A systematic review of bevacizumab efficacy in breast cancer","volume":"40","author":"K\u00fcmler","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(13)70335-8","article-title":"Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial","volume":"14","author":"Cameron","year":"2013","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.03.4645","article-title":"Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer","volume":"24","author":"Wedam","year":"2006","journal-title":"J Clin Oncol"},{"key":"B16","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Stat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1111097","article-title":"Bevacizumab added to neoadjuvant chemotherapy for breast cancer","volume":"366","author":"Bear","year":"2012","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw665","article-title":"Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer","volume":"28","author":"Bell","year":"2017","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1111065","article-title":"Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)\u2020","volume":"25","author":"von Minckwitz","year":"2014","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-0160","article-title":"The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer","volume":"23","author":"Silwal-Pandit","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3889-6","article-title":"SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer","volume":"158","author":"Nahleh","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01506","article-title":"CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer","volume":"40","author":"Shepherd","year":"2022","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)70137-3","article-title":"Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial","volume":"16","author":"Earl","year":"2015","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100566","article-title":"Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study","volume":"28","author":"Coudert","year":"2020","journal-title":"EClinicalMedicine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8050612","article-title":"Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer","volume":"8","author":"Sabatier","year":"2019","journal-title":"J Clin Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt361","article-title":"Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)","volume":"24","author":"Gerber","year":"2013","journal-title":"Ann Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41698-021-00197-w","article-title":"Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients","volume":"5","author":"Boucher","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/s41419-020-03161-x","article-title":"Tumor necrosis factor \u03b1 inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01875","article-title":"Onco-Hypertension: Changing Paradigm of Treating Hypertension in Patients With Cancer","volume":"41","author":"Sahni","year":"2023","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.19.8721","article-title":"Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma","volume":"41","author":"Friedman","year":"2023","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217851","article-title":"Transarterial chemoembolization combined with intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: a phase 2 study","volume":"628","author":"Mu","year":"2025","journal-title":"Cancer Lett"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34559","article-title":"Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice","volume":"129","author":"Nakagawa","year":"2023","journal-title":"Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.3395","article-title":"Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial","volume":"8","author":"Morizane","year":"2022","journal-title":"JAMA Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100293","article-title":"Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI\/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO","volume":"6","author":"Rossini","year":"2021","journal-title":"ESMO Open"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000002528","article-title":"Efficacy and safety of neoadjuvant ICI combined with chemotherapy in breast cancer from the perspective of a privileged population: a systematic review and meta-analysis","volume":"111","author":"Liu","year":"2025","journal-title":"Int J Surg"},{"key":"B38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13058-024-01788-8","article-title":"Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers","volume":"26","author":"Derouane","year":"2024","journal-title":"Breast Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13058-024-01944-0","article-title":"Stromal tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: a single-center real-world study","volume":"26","author":"Bae","year":"2024","journal-title":"Breast Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"218610","DOI":"10.1016\/j.canlet.2026.218610","article-title":"Biomarker-Guided Strategies for Tumor Vasculature: From Imaging Advances to Novel Therapeutic Interventions","author":"Purcell","year":"2026","journal-title":"Cancer Lett"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.029","article-title":"PI3K\u03b3\u03b4 inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model","volume":"157","author":"Han","year":"2021","journal-title":"Eur J Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.07.162","article-title":"The Evolution of Acquired Resistance to BRAF(V600E) kinase inhibitor Is Sustained by IGF1-Driven Tumor Vascular Remodeling","volume":"142","author":"Xu","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btae590","article-title":"BEATRICE: Bayesian fine-mapping from summary data using deep variational inference","volume":"40","author":"Ghosal","year":"2024","journal-title":"Bioinformatics"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-22-0287","article-title":"Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma","volume":"12","author":"Bosse","year":"2022","journal-title":"Cancer Discov"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-026-01126-1","article-title":"Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling","volume":"23","author":"Martini","year":"2026","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1830676\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:22:06Z","timestamp":1784089326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1830676\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":45,"alternative-id":["10.3389\/fonc.2026.1830676"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1830676","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1830676"}}